TSHA
Taysha Gene Therapies, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Taysha Gene Therapies has 9 disclosed suppliers and 2 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.12%
vs ±13.4% implied · ×0.31
shaded = implied · ▲▼ = realized
SentenceIn connection with the Abeona CLN1 Agreement, we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy for the prevention, treatment, or diagnosis of CLN1 Disease (one of the forms of Batten disease) in humans.
TSHA 10-Kaccession 0001193125-26-115202
SentenceTo date, our manufacturing partners have met our manufacturing requirements and quality standards for our program materials, and we expect that these organizations, primarily Catalent, will be capable of providing sufficient quantities of our program materials to meet anticipated clinical trial scale demands.
TSHA 10-Kaccession 0001193125-26-115202
SentenceOn November 4, 2025, we and Leerink Partners LLC entered into an Amendment to the Sales Agreement pursuant to which the Sales Agreement was terminated solely with respect to Leerink Partners LLC.
TSHA 10-Kaccession 0001193125-26-115202
SentenceSSI provides certain consulting services to us.
TSHA 10-Kaccession 0001193125-26-115202
SentenceIn connection with the UT Southwestern Agreement, we obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications.
TSHA 10-Kaccession 0001193125-26-115202
SentenceIn connection with the UT Southwestern Agreement, we issued to UT Southwestern 2,179,000 shares of our common stock.
TSHA 10-Kaccession 0001193125-26-115202
SentenceIn November 2019, we entered into the UT Southwestern Agreement with The Board of Regents of the University of Texas System on behalf of UT Southwestern, as amended in April 2020.
TSHA 10-Kaccession 0001193125-26-115202
SentenceUnder the Abeona Rett Agreement, we also sub-license from the University of North Carolina at Chapel Hill 9 pending patent applications worldwide directed to feedback-enabled synthetic genes that inhibit MECP2 expression and use of these synthetic genes for treating Rett Syndrome.
TSHA 10-Kaccession 0001193125-26-115202
SentenceOn October 21, 2022, or the Effective Date, we entered into the Option Agreement with Astellas.
TSHA 10-Kaccession 0001193125-26-115202
Sentence
During the year ended December 31, 2025, SSI exercised all 316,667 vested and outstanding Warrant Shares.
TSHA 10-Kaccession 0001193125-26-115202
Taysha Gene Therapies, Inc.
4.12
Linked news
Expected move
Inputs8Q avg ±4.0%·×1.93·rich
straddle ±17.0%
spot 4.13exp Nov 20ATM strike 4ATM straddle 0.82IV 107%